XNASARTV
Market cap158mUSD
Jan 17, Last price
6.53USD
1D
-3.69%
1Q
-46.34%
IPO
-44.52%
Name
Artiva Biotherapeutics Inc
Chart & Performance
P/E
—
P/S
4.74
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
33m
+579.21%
Net income
-28m
L-52.57%
CFO
-47m
L-6.69%
Profile
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 33,492 579.21% | 4,931 146.30% | |||
Cost of revenue | 64,163 | 64,760 | |||
Unusual Expense (Income) | |||||
NOPBT | (30,671) | (59,829) | |||
NOPBT Margin | |||||
Operating Taxes | 72 | 53 | |||
Tax Rate | |||||
NOPAT | (30,743) | (59,882) | |||
Net income | (27,696) -52.57% | (58,388) -18.71% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | (12) | (5) | |||
BB yield | |||||
| Debt | |||||
Debt current | 3,596 | 3,486 | |||
Long-term debt | 30,228 | 35,410 | |||
Deferred revenue | 15,635 | ||||
Other long-term liabilities | 241,586 | 115 | |||
Net debt | (43,147) | (63,635) | |||
| Cash flow | |||||
Cash from operating activities | (47,430) | (50,829) | |||
CAPEX | (3,258) | (6,299) | |||
Cash from investing activities | (25,975) | (6,299) | |||
Cash from financing activities | 24,391 | (1,264) | |||
FCF | (27,774) | (83,416) | |||
| Balance | |||||
Cash | 76,971 | 102,531 | |||
Long term investments | |||||
Excess cash | 75,296 | 102,284 | |||
Stockholders' equity | (181,003) | (152,591) | |||
Invested Capital | 277,486 | 47,093 | |||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 9,355 | 17,583 | |||
Price | |||||
Market cap | |||||
EV | |||||
EBITDA | (28,405) | (58,671) | |||
EV/EBITDA | |||||
Interest | |||||
Interest/NOPBT | |||||